RC-1291

Known as: ONO-7643, RC-1291 ghrelin mimetic 
A synthetic, orally bioavailable, small-molecule ghrelin mimetic with appetite-stimulating and anabolic activities. RC-1291 ghrelin mimetic binds to… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2018
0120072018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Cachexia, described as weight loss (mainly in lean body mass [LBM]) and anorexia, is common in patients with advanced… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
Cancer cachexia is characterized by decreased body weight (mainly lean body mass [LBM]) and negatively impacts quality of life… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • table 2
Is this relevant?
2014
2014
BACKGROUND Anamorelin HCl (ANAM) is a novel, orally active, ghrelin receptor agonist in clinical development for the treatment of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 6
Is this relevant?
2013
2013
Anamorelin (ONO-7643) is an orally active ghrelin receptor agonist in development for non-small cell lung cancer (NSCLC)-related… (More)
  • figure 1
  • table 1
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
2007
2007
PURPOSE RC-1291 is a novel, oral ghrelin mimetic and growth hormone (GH) secretagogue being developed to increase appetite and… (More)
Is this relevant?